• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    3/24/23 1:03:34 PM ET
    $ADMA
    $ALLR
    $BAOS
    $BOXD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADMA alert in real time by email

    Gainers

    • Near Intelligence Inc. (NASDAQ:NIR) shares climbed 53.1% to $16.50.
    • Silvergate Capital Corporation (NYSE:SI) climbed 48% to $1.67 on rumor suggesting a crypto exchange is trying to buy Silvergate's trade processing technologies.
    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) gained 33.9% to $2.2499 after jumping 25% on Thursday. Maxim Group maintained Dermata Therapeutics with a Buy and lowered the price target from $16 to $4.
    • NaaS Technology Inc. (NASDAQ:NAAS) jumped 25.7% to $5.24. NaaS Technology will hold an annual general meeting of shareholders on April 19, 2023.
    • GH Research PLC (NASDAQ:GHRS) gained 25.5% to $8.68.
    • Vaccitech plc (NASDAQ:VACC) climbed 25.4% to $2.8355 after the company reported better-than-expected FY22 sales results.
    • Troika Media Group, Inc. (NASDAQ:TRKA) rose 23.4% to $0.2205.
    • GD Culture Group Limited (NASDAQ:GDC) gained 22.8% to $3.2899.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) jumped 21.5% to $2.09.
    • Bird Global, Inc. (NYSE:BRDS) shares rose 19.3% to $0.1691 after gaining more than 17% on Thursday. Bird announced plans to expand across Greater Toronto area this spring.
    • Torrid Holdings Inc. (NYSE:CURV) gained 18.1% to $2.81 after the company reported Q4 results.
    • Vicarious Surgical Inc. (NYSE:RBOT) jumped 16% to $1.74.
    • Usio, Inc. (NASDAQ:USIO) jumped 15.7% to $1.98.
    • Xcel Brands, Inc. (NASDAQ:XELB) gained 14.5% to $0.70.
    • Vor Biopharma Inc. (NASDAQ:VOR) jumped 13.7% to $5.80 following a narrower-than-expected quarterly loss.
    • ReNew Energy Global Plc (NASDAQ:RNW) gained 13.6% to $4.99.
    • Reading International, Inc. (NASDAQ:RDIB) surged 8% to $22.14.
    • ADMA Biologics, Inc. (NASDAQ:ADMA) shares climbed 6.8% to $3.3215 after the company reported better-than-expected Q4 sales results and issued FY23 revenue guidance above estimates.

    Losers

    • Boxed, Inc. (NYSE:BOXD) fell 35.8% to $0.2209 after gaining 91% on Thursday. Boxed recently said it is evaluating potentially filing for relief under the U.S. Bankruptcy Code and other strategic alternatives.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares dropped 32% to $0.0767 after the company announced a reverse stock split of its common stock.
    • FiscalNote Holdings, Inc. (NYSE:NOTE) shares tumbled 29.4% to $1.6799. FiscalNote shares jumped 75% on Thursday after the company announced it was selected by OpenAI for collaboration as an inaugural launch partner for OpenAI's ChatGPT plug-in.
    • Hyzon Motors Inc. (NASDAQ:HYZN) fell 25.4% to $0.7456.
    • Scholastic Corporation (NASDAQ:SCHL) fell 23% to $31.82 after the company said Q3 adjusted EPS and sales results were lower year over year.
    • YS Biopharma Co., Ltd. (NASDAQ:YS) dipped 22% to $10.14.
    • Sentage Holdings Inc. (NASDAQ:SNTG) dropped 20.8% to $2.05.
    • DiamondHead Holdings Corp. (NASDAQ:DHHC) fell 19.8% to $15.15 after gaining more than 82% on Thursday. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.
    • Cidara Therapeutics, Inc. (NASDAQ:CDTX) dropped 17.7% to $1.1750. HC Wainwright & Co. reiterated Cidara Therapeutics with a Buy and maintained a $6 price target.
    • Baosheng Media Group Holdings Limited (NASDAQ:BAOS) fell 17.7% to $3.53.
    • Express, Inc. (NYSE:EXPR) fell 16.2% to $0.7122 after the company reported worse-than-expected Q4 sales results.
    • Flora Growth Corp. (NASDAQ:FLGC) fell 15.4% to $0.2360. Flora Growth is expected to host its 2022 year-end earnings call on Monday, April 3, 2023.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares fell 14.2% to $1.10 after jumping over 35% on Thursday.
    • Oxford Industries, Inc. (NYSE:OXM) dropped 13.2% to $101.06 after the company issued Q1 adjusted EPS guidance below estimates.
    • Ouster, Inc. (NYSE:OUST) fell 12.5% to $0.7909 after the company reported downbeat Q4 results and issued weak Q1 sales forecast.
    • PepGen Inc. (NASDAQ:PEPG) fell 12.3% to $14.79 following Q4 results.
    • Invivyd, Inc. (NASDAQ:IVVD) dropped 11.2% to $1.2685. Invivyd posted a FY22 loss of $2.23 per share.
    • Lilium N.V. (NASDAQ:LILM) fell 10.8% to $0.7089.
    • Heron Therapeutics, Inc. (NASDAQ:HRTX) fell 10.7% to $1.8450 after posting Q4 results.
    • Proterra Inc. (NASDAQ:PTRA) dropped 10.1% to $1.5199.
    • PARTS iD, Inc. (NYSE:ID) fell 8.6% to $0.2146.
    • Farfetch Limited (NYSE:FTCH) fell 7% to $4.3450. Citigroup maintained Farfetch with a Sell and lowered the price target from $6 to $4.
    • Getty Images Holdings, Inc. (NYSE:GETY) fell 6.9% to $3.75.

    Now Read This: Bitcoin, Ethereum Move Higher; Mask Network, Mina Among Top Gainers

    Get the next $ADMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMA
    $ALLR
    $BAOS
    $BOXD

    CompanyDatePrice TargetRatingAnalyst
    Oxford Industries Inc.
    $OXM
    1/13/2026$35.00 → $40.00Market Perform
    Telsey Advisory Group
    Vor Biopharma Inc.
    $VOR
    1/9/2026$50.00Buy
    Citigroup
    Invivyd Inc.
    $IVVD
    12/22/2025$10.00Buy
    BTIG Research
    Vor Biopharma Inc.
    $VOR
    12/17/2025Buy
    TD Cowen
    Oxford Industries Inc.
    $OXM
    12/11/2025$52.00 → $35.00Market Perform
    Telsey Advisory Group
    Vor Biopharma Inc.
    $VOR
    12/9/2025$43.00Overweight
    Analyst
    Vor Biopharma Inc.
    $VOR
    11/25/2025$9.00Neutral
    Wedbush
    Oxford Industries Inc.
    $OXM
    11/25/2025$35.00Sell → Neutral
    Citigroup
    More analyst ratings

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Hykes Andrew

    3 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/4/26 4:20:48 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    CEO and Chairman D Loren Robert W was granted 20,425 shares and covered exercise/tax liability with 10,519 shares, increasing direct ownership by 1% to 720,032 units (SEC Form 4)

    4 - XCel Brands, Inc. (0001083220) (Issuer)

    3/3/26 6:28:22 PM ET
    $XELB
    Multi-Sector Companies
    Miscellaneous

    President and CEO Grossman Adam S covered exercise/tax liability with 54,858 shares, decreasing direct ownership by 2% to 2,204,728 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    3/2/26 9:00:14 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Oxford Industries with a new price target

    Telsey Advisory Group reiterated coverage of Oxford Industries with a rating of Market Perform and set a new price target of $40.00 from $35.00 previously

    1/13/26 8:19:44 AM ET
    $OXM
    Garments and Clothing
    Industrials

    Citigroup initiated coverage on Vor Biopharma with a new price target

    Citigroup initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $50.00

    1/9/26 9:08:27 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BTIG Research initiated coverage on Invivyd with a new price target

    BTIG Research initiated coverage of Invivyd with a rating of Buy and set a new price target of $10.00

    12/22/25 8:39:25 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Torrid Announces Reporting Date for Fourth Quarter and Fiscal 2025 Financial Results

    Torrid Holdings Inc. ("Torrid" or the "Company") (NYSE:CURV), a direct-to-consumer apparel, intimates, and accessories brand in North America for women sizes 10 to 30, today announced that it will release fourth quarter and fiscal 2025 financial results after market close on Thursday, March 19, 2026. Management will host a conference call that afternoon at 4:30 p.m. Eastern Time to discuss its financial results. Those who wish to participate in the call may do so by dialing (877) 407-9208 or (201) 493-6784 for international callers. The conference call will also be webcast live at https://investors.torrid.com. For those unable to participate, a replay of the conference call will be avai

    3/5/26 4:05:00 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Scholastic Corporation Announces Date for Third Quarter Fiscal 2026 Earnings Release and Conference Call

    NEW YORK, March 5, 2026 /PRNewswire/ -- Scholastic Corporation (NASDAQ:SCHL) today announced the following schedule and conference call information for its third quarter fiscal year 2026 earnings announcement: Earnings Release: Thursday, March 19, 2026, at 4:00 PM ET and posted on the Company's investor relations website, investor.scholastic.com.Conference Call: Thursday, March 19, 2026, at 4:30 PM ET hosted by Peter Warwick, President and CEO, and Haji Glover, CFO and Executive Vice President. A live webcast of the call can be accessed at https://edge.media-server.com/mmc/p/6ck

    3/5/26 4:01:00 PM ET
    $SCHL
    Books
    Consumer Discretionary

    Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

    Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025DECLARATION trial on track with full enrollment achievedDECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC re

    3/5/26 7:03:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    SEC Filings

    View All

    SEC Form S-8 filed by GH Research PLC

    S-8 - GH Research PLC (0001855129) (Filer)

    3/5/26 8:30:46 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Invivyd Inc.

    10-K - Invivyd, Inc. (0001832038) (Filer)

    3/5/26 7:20:57 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

    8-K - Invivyd, Inc. (0001832038) (Filer)

    3/5/26 7:11:42 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner National Services, Inc bought $411,562 worth of shares (198,232 units at $2.08) and sold $44,498 worth of shares (31,897 units at $1.40), increasing direct ownership by 6% to 2,813,172 units (SEC Form 4)

    4 - Usio, Inc. (0001088034) (Issuer)

    12/29/25 6:08:22 AM ET
    $USIO
    Investment Bankers/Brokers/Service
    Finance

    CEO and Chairman D Loren Robert W bought $94,908 worth of shares (81,466 units at $1.17), increasing direct ownership by 13% to 687,297 units (SEC Form 4)

    4 - XCel Brands, Inc. (0001083220) (Issuer)

    12/19/25 12:42:34 PM ET
    $XELB
    Multi-Sector Companies
    Miscellaneous

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    Leadership Updates

    Live Leadership Updates

    View All

    Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

    Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital, Dr. Mina strengthens Invivyd's medical leadership Dr. Mina's research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipelineWith more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and conveying its meaning and impact to healthc

    3/5/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors

    GRAND RAPIDS, Mich., March 2, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board.   "Drew is a proven healthcare leader, and we are thrilled to welcome him to S

    3/2/26 7:00:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previo

    2/25/26 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    Financials

    Live finance-specific insights

    View All

    Torrid Announces Reporting Date for Fourth Quarter and Fiscal 2025 Financial Results

    Torrid Holdings Inc. ("Torrid" or the "Company") (NYSE:CURV), a direct-to-consumer apparel, intimates, and accessories brand in North America for women sizes 10 to 30, today announced that it will release fourth quarter and fiscal 2025 financial results after market close on Thursday, March 19, 2026. Management will host a conference call that afternoon at 4:30 p.m. Eastern Time to discuss its financial results. Those who wish to participate in the call may do so by dialing (877) 407-9208 or (201) 493-6784 for international callers. The conference call will also be webcast live at https://investors.torrid.com. For those unable to participate, a replay of the conference call will be avai

    3/5/26 4:05:00 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Scholastic Corporation Announces Date for Third Quarter Fiscal 2026 Earnings Release and Conference Call

    NEW YORK, March 5, 2026 /PRNewswire/ -- Scholastic Corporation (NASDAQ:SCHL) today announced the following schedule and conference call information for its third quarter fiscal year 2026 earnings announcement: Earnings Release: Thursday, March 19, 2026, at 4:00 PM ET and posted on the Company's investor relations website, investor.scholastic.com.Conference Call: Thursday, March 19, 2026, at 4:30 PM ET hosted by Peter Warwick, President and CEO, and Haji Glover, CFO and Executive Vice President. A live webcast of the call can be accessed at https://edge.media-server.com/mmc/p/6ck

    3/5/26 4:01:00 PM ET
    $SCHL
    Books
    Consumer Discretionary

    Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

    Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025DECLARATION trial on track with full enrollment achievedDECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC re

    3/5/26 7:03:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $ALLR
    $BAOS
    $BOXD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Torrid Holdings Inc.

    SC 13G - Torrid Holdings Inc. (0001792781) (Subject)

    12/12/24 6:06:52 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary